 |
|
Use of dapagliflozin in patients with advanced diabetic kidney disease
Hyun Sun Park, Youn Joo Jung, Dong-Young Lee, Kyoung Hyoub Moon, Beom Kim, Hae Won Kim
Kidney Res Clin Pract. 2018;37(3):292-297. Published online 2018 Sep 30 DOI: https://doi.org/10.23876/j.krcp.2018.37.3.292
|
|
Citations to this article as recorded by
 The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
Vandana Veenit, Hiddo J L Heerspink, Christine Ahlström, Peter J Greasley, Stanko Skritic, Natalie van Zuydam, Donald E Kohan, Pernille B L Hansen, Robert I Menzies
Nephrology Dialysis Transplantation.2023; 38(10): 2289. CrossRef A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
Allen Yan Lun Liu, Serena Low, Ester Yeoh, Eng Kuang Lim, Claude Jeffrey Renaud, Selene Tse Yen Teoh, Grace Feng Ling Tan, Chung Cheen Chai, Bo Liu, Tavintharan Subramaniam, Chee Fang Sum, Su Chi Lim
Clinical Kidney Journal.2022; 15(7): 1403. CrossRef Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes
Ashley S Cha, Yilin Chen, Katherine Fazioli, Matthew B Rivara, Emily Beth Devine
The Journal of Clinical Endocrinology & Metabolism.2021; 106(4): 1225. CrossRef Aktuelles zur evidenzbasierten medikamentösen Herzinsuffizienztherapie
I. E. Emrich, J. Wintrich, I. Kindermann, M. Böhm
Herz.2020; 45(S1): 37. CrossRef Dapagliflozin/furosemide
Reactions Weekly.2018; 1724(1): 133. CrossRef
|